Floatz logo

WARFARIN

Portal Vein Thrombosis

Kafrelsheikh UniversitySmall moleculePhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
81/ 100

Competitive context

13 Active assets in the Portal Vein Thrombosis cohort.

Asset / SponsorPhaseRating
Sorafenib
First Affiliated Hospital of Zhejiang University
Phase 4BBB
LENVATINIB
First Hospital of China Medical University
Phase 4BBB
NADROPARIN
Shanghai Zhongshan Hospital
Phase 4BB
Enoxaparin
Institute of Liver and Biliary Sciences, India
Phase 4BB
CARVEDILOL
Asian Institute Of Medical Sciences
Phase 4B

View all 27 →

Same molecule, other indications

WARFARIN is also rated in:

venous thromboembolismDormant
A
Indicative ·
81 / 100
View asset →
atrial fibrillationDormant
BBB
Indicative ·
77 / 100
View asset →
hemorrhagic diseaseDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →